New combo therapy shows promise for incurable head and neck cancer
NCT ID NCT03494322
First seen May 20, 2026 · Last updated May 26, 2026 · Updated 1 time
Summary
This study tested whether adding cetuximab to the immunotherapy drug avelumab works better than avelumab alone for advanced head and neck cancer that has returned or spread. The trial included a small safety check first, then planned to enroll 114 patients across UK hospitals. Treatment lasted up to a year, with follow-up for two years, aiming to see if the combination improves disease control and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University College Hospital
London, NW1 2PG, United Kingdom
Conditions
Explore the condition pages connected to this study.